Search results
Results from the WOW.Com Content Network
Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. [5] This includes bone and joint infections, intra-abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. [5]
Rash. Lacks known anemic side-effects. A chloramphenicol analog. May inhibit bacterial protein synthesis by binding to the 50S subunit of the ribosome Tigecycline(Bs) Tigacyl: Slowly Intravenous. Indicated for complicated skin/skin structure infections, soft tissue infections and complicated intra-abdominal infections.
Quinolone antibiotics constitute a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. [1] They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production.
The most reported adverse effects of phase I studies included headache, rhinitis, pain, dyspepsia, and dysmenorrhea. Investigators did not believe that any of these were directly treatment-related, as many of these events are considered symptoms or manifestations of the underlying illness.
The term injection encompasses intravenous (IV), intramuscular (IM), subcutaneous (SC) and intradermal (ID) administration. [ 35 ] Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often occurring in 15–30 seconds for IV, 10–20 minutes for IM and 15–30 minutes for SC. [ 36 ]
Ciprofloxacin/celecoxib or PrimeC is a fixed-dose combination of ciprofloxacin and celecoxib developed for ALS. [1] [2] References
The United Kingdom's Health Protection Agency has stated that "most isolates with NDM-1 enzyme are resistant to all standard intravenous antibiotics for treatment of severe infections." [ 100 ] On 26 May 2016, an E. coli " superbug " was identified in the United States resistant to colistin , "the last line of defence" antibiotic .
The main result was a relative risk (RR) of 0.40 (95% confidence interval (CI) 0.31 to 0.52) for development of active tuberculosis over two years or longer for patients treated with INH, with no significant difference between treatment courses of six or 12 months (RR 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for ...